JOAN FRAINO: Open Payments
NPI 1487025375 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,513 in 89 payments from 12 companies in 2025. Trend: 2023 $764 · 2024 $981 · 2025 $2,513
Food & beverage: $2,314Education: $199
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 38 | $1,024 |
| Novo Nordisk Inc | 11 | $432 |
| E.R. Squibb & Sons, L.L.C. | 15 | $416 |
| Janssen Pharmaceuticals, Inc | 7 | $177 |
| Alkermes, Inc. | 5 | $154 |
| Otsuka America Pharmaceutical, Inc. | 3 | $82 |
| SCILEX PHARMACEUTICALS INC. | 4 | $80 |
| Lilly USA, LLC | 2 | $56 |
| Seqirus USA Inc | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: UZEDY, COBENFY, Ozempic, INVEGA SUSTENNA, Wegovy, ARISTADA, LYBALVI, REXULTI.
Industry payments across ID — which companies pay providers there.
